Crescita Therapeutics Inc.
CRRTF
$0.31
-$0.04-10.71%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.08% | 82.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.08% | 82.80% | |||
| Cost of Revenue | 5.88% | 39.54% | |||
| Gross Profit | -25.02% | 127.11% | |||
| SG&A Expenses | -8.80% | 22.60% | |||
| Depreciation & Amortization | 9.29% | 3.70% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.23% | 27.43% | |||
| Operating Income | -127.91% | 156.95% | |||
| Income Before Tax | -5.22% | 188.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.22% | 188.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.22% | 188.82% | |||
| EBIT | -127.91% | 156.95% | |||
| EBITDA | -76.17% | 236.94% | |||
| EPS Basic | -4.92% | 189.44% | |||
| Normalized Basic EPS | 31.05% | 189.20% | |||
| EPS Diluted | 0.35% | 184.75% | |||
| Normalized Diluted EPS | 31.75% | 188.73% | |||
| Average Basic Shares Outstanding | -0.51% | -0.50% | |||
| Average Diluted Shares Outstanding | -0.99% | 0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||